Pfizer boss does not rule out a multivariant vaccine in the fall

A vaccine against COVID-19 effective against multiple variants by the fall “is a possibility, but not a certainty”, said Wednesday the boss of the American pharmaceutical giant Pfizer, Albert Bourla.

• Read also: Quebec has more than 2,000 hospitalizations

• Read also: Rise in COVID-19 cases: Legault must take up the torch, say opposition parties

“I hope that by the fall – but it is not a certainty – we could have a vaccine” which is effective “against everything that is known at the moment”, underlined Mr. Bourla, during a press briefing organized by the International Federation of the Pharmaceutical Industry (Ifpma).

Pfizer is currently conducting studies to find out what might be the best formula.

“Once we have the data that allows us to decide which (vaccine) is the best,” Bourla said.

Pfizer and Germany’s Biontech have developed one of the first and most effective COVID-19 vaccines injected for the first time in the UK at the end of 2020, less than a year after the disease was detected in China .

This messenger RNA vaccine – like that of Moderna – has seen its effectiveness reduced against the Omicron variant of the virus and its sub-variants which give COVID-19, even if it still protects very effectively against serious symptoms, hospitalizations and the death.

Pfizer is currently testing different vaccines and different doses.

“Once we know it’s the best way forward, we’ll seek approval” in the United States, Europe and elsewhere in the world, he said.

Leave a Comment